Primary hypertrophic osteoarthropathy: an update

Zeng Zhang; Changqing Zhang; Zhenlin Zhang

doi:10.1007/s11684-013-0246-6

Primary hypertrophic osteoarthropathy: an update

Front Med. 2013 Mar;7(1):60-4. doi: 10.1007/s11684-013-0246-6. Epub 2013 Jan 23.

Authors

Zeng Zhang¹, Changqing Zhang, Zhenlin Zhang

Affiliation

¹ Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Diseases, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.

PMID: 23345113
DOI: 10.1007/s11684-013-0246-6

Abstract

Digital clubbing, which has been recognized as a sign of systemic disease, is one of the most ancient diseases. However, the pathogenesis of clubbing and hypertrophic osteoarthropathy has hitherto been poorly understood. The study of a clinically indistinguishable idiopathic form (primary hypertrophic osteoarthropathy, PHO) provides an opportunity to understand the pathogenesis of hypertrophic osteoarthropathy. Current advances in the study of PHO are discussed. The impaired metabolism of prostaglandin E2 (PGE2) plays a central role in its pathogenesis.

Publication types

Review

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Diagnosis, Differential
Dinoprostone / metabolism*
Glucocorticoids / therapeutic use
Humans
Osteoarthropathy, Primary Hypertrophic* / complications
Osteoarthropathy, Primary Hypertrophic* / diagnosis
Osteoarthropathy, Primary Hypertrophic* / drug therapy
Osteoarthropathy, Primary Hypertrophic* / metabolism
Osteoarthropathy, Primary Hypertrophic* / physiopathology
Osteoarthropathy, Secondary Hypertrophic* / diagnosis
Osteoarthropathy, Secondary Hypertrophic* / etiology
Osteoarthropathy, Secondary Hypertrophic* / metabolism
Osteoarthropathy, Secondary Hypertrophic* / physiopathology
Osteogenesis
Treatment Outcome

Substances

Anti-Inflammatory Agents, Non-Steroidal
Glucocorticoids
Dinoprostone